Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemotherapy Resistance: Role of Mitochondrial and Autophagic Components.

Cancers·2022
Same author

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs.

Pharmaceuticals (Basel, Switzerland)·2021
Same author

Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer.

Pharmaceuticals (Basel, Switzerland)·2021
Same author

Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.

Investigational new drugs·2017

Related Experiment Video

Updated: Sep 29, 2025

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.7K

Small Molecule Induced FLT3 Degradation.

Sun-Young Han1

  • 1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju-daero, Jinju-si 52828, Korea.

Pharmaceuticals (Basel, Switzerland)
|March 26, 2022
PubMed
Summary

Targeted protein degraders offer a novel approach for treating acute myeloid leukemia (AML) by downregulating Fms-like tyrosine kinase 3 (FLT3). This strategy aims to overcome resistance to existing FLT3 inhibitors.

Keywords:
fms-like tyrosine kinase 3heat shock protein 90target protein degraderubiquitin proteasome system

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

12.2K

Related Experiment Videos

Last Updated: Sep 29, 2025

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.7K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

12.2K

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Discovery

Background:

  • Fms-like tyrosine kinase 3 (FLT3) is a key target in acute myeloid leukemia (AML).
  • Existing FLT3 kinase inhibitors face challenges due to emerging drug resistance.
  • Novel therapeutic strategies are needed to overcome resistance and improve AML treatment outcomes.

Purpose of the Study:

  • To explore targeted protein degraders as a new paradigm in small molecule drug discovery for AML.
  • To discuss the potential of downregulating FLT3 protein levels to combat AML.
  • To review mechanisms for overcoming FLT3 inhibitor resistance.

Main Methods:

  • Literature review of small molecules targeting FLT3 degradation.
  • Discussion of mechanisms including Hsp90 inhibition, proteasome inhibition, RET inhibition, and USP10 inhibition.
  • Analysis of FLT3's role as an Hsp90 client and its degradation via the ubiquitin proteasome system.

Main Results:

  • Small molecules that downregulate FLT3 protein exhibit antileukemic effects in AML cell lines.
  • FLT3 has been identified as a client of Heat Shock Protein 90 (Hsp90).
  • FLT3 degradation is linked to the ubiquitin proteasome system and phosphorylation status.

Conclusions:

  • Targeted protein degradation represents a promising 'event-driven pharmacology' approach for AML.
  • Strategies targeting FLT3 degradation pathways may overcome resistance to current FLT3 inhibitors.
  • Further research into FLT3 degradation mechanisms could lead to novel AML therapeutics.